Center for Pharmacy Innovation and Outcomes, Geisinger Precision Health Center, Forty Fort, PA, USA.
BMC Med. 2018 Oct 5;16(1):169. doi: 10.1186/s12916-018-1160-1.
Emergency hospital admissions are common, with several interventions having been developed to reduce their rates. Bobrovitz et al. summarized the available body of evidence regarding pharmacologic therapies aimed at reducing emergency hospital admissions, and identified 28 medications for which high- or moderate-quality evidence supports their use, 11 of which were identified as being supported by current guideline recommendations. Additionally, the authors identified 28 medications supported by low- or very low-quality evidence, which can serve as targets for future research. The article by Bobrovitz et al. presents a good summary of the evidence, albeit with limitations in the search strategy that cannot guarantee the review as comprehensive. Despite this, the review has important implications for policymakers, guideline panels, researchers, clinicians, and funders since the identified medications can either be targets for quality improvement initiatives or for future research. Bobrovitz et al.'s review highlights the challenge that systematic reviewers face when balancing feasibility and comprehensiveness.Please see related article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1104-9.
急诊住院很常见，已经开发了多种干预措施来降低其发生率。Bobrovitz 等人总结了现有的针对降低急诊住院率的药物治疗的证据，确定了 28 种药物具有高质量或中等质量的证据支持其使用，其中 11 种被认为得到了当前指南建议的支持。此外，作者还确定了 28 种药物得到了低质量或极低质量证据的支持，这些药物可以作为未来研究的目标。Bobrovitz 等人的文章很好地总结了证据，尽管搜索策略存在局限性，无法保证综述的全面性。尽管如此，由于确定的药物可以是质量改进举措或未来研究的目标，因此该综述对政策制定者、指南制定小组、研究人员、临床医生和资助者具有重要意义。Bobrovitz 等人的综述突出了系统评价者在平衡可行性和全面性方面面临的挑战。请参阅相关文章：https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1104-9。
